Status:
COMPLETED
Observational to Investigate the Efficacy of CRESTOR 5mg in Reaching LDL-C Target Goals in Patients Who Are at High Risk for a Cardiovascular Event
Lead Sponsor:
AstraZeneca
Conditions:
Hypercholesteremia
Eligibility:
All Genders
Brief Summary
Observational study to investigate the use and efficacy of CRESTOR 5 mg in reaching LDL-C target goals in both statin naïve and statin treated primary and secondary prevention patients at high risk fo...
Eligibility Criteria
Inclusion
- The patient has a high risk of a cardiovascular event as defined by the European guidelines.
- The patient is statin-naive (i.e. has not used a statin \> 2 months), or is currently treated with atorvastatin, pravastatin or simvastatin.
- An LDL-C level is known for the statin-naive patient or for the statin used during visit 1.
- It has been decided to start the patient on CRESTOR 5 mg.
- The patient is prepared to give permission to the coded data being made available to AstraZeneca
Exclusion
- The patient is known to have complaints of myalgia, myopathy or liver function impairment (including elevated levels of serum transaminases) where there is a causal relationship with the statin treatment.
- Contraindications for treatment with CRESTOR (see 1 B1 text).
- Patients with a family history of dyslipidemias, for instance familiar (combined) hypercholesterolemia
Key Trial Info
Start Date :
February 1 2006
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2009
Estimated Enrollment :
3840 Patients enrolled
Trial Details
Trial ID
NCT00347217
Start Date
February 1 2006
End Date
January 1 2009
Last Update
August 30 2011
Active Locations (215)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
's-Hertogenbosch, Netherlands
2
Research Site
't Zand Nh, Netherlands
3
Research Site
Alblasserdam, Netherlands
4
Research Site
Alkmaar, Netherlands